|
|
Article: Acadia makes new move for an IPO: Neurocrine Biosciences spends $95 million to buy back drug rights.(Biotech )(Brief Article)
- Article from:
- San Diego Business Journal
- Article date:
- March 8, 2004
- Author:
CopyrightCOPYRIGHT 2004 CBJ, L.P. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
San Diego-based biotech company Acadia Pharmaceuticals Inc. is making its second attempt to go public.
On Feb. 27, Acadia Pharmaceuticals filed an initial public offering to sell up to $86.25 million in common stock.
Details on the number of shares offered and estimated price range for the IPO were not disclosed.
On Aug. 31, 2001, Acadia ...